Raymond James Financial Inc. Acquires New Shares in Evolus, Inc. (NASDAQ:EOLS)

Raymond James Financial Inc. bought a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 52,035 shares of the company's stock, valued at approximately $575,000. Raymond James Financial Inc. owned approximately 0.08% of Evolus at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC grew its stake in Evolus by 268.0% in the 3rd quarter. Barclays PLC now owns 93,662 shares of the company's stock worth $1,518,000 after buying an additional 68,213 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company's stock worth $6,781,000 after acquiring an additional 265,635 shares in the last quarter. Principal Financial Group Inc. increased its stake in Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after acquiring an additional 2,989 shares during the last quarter. Jane Street Group LLC raised its position in Evolus by 47.0% during the third quarter. Jane Street Group LLC now owns 91,899 shares of the company's stock valued at $1,489,000 after purchasing an additional 29,396 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after purchasing an additional 188,685 shares during the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now directly owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock valued at $794,369 over the last quarter. 6.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EOLS shares. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday. Finally, Barclays lifted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th.

Evolus Trading Up 1.4 %

NASDAQ EOLS traded up $0.13 on Friday, hitting $9.54. The company's stock had a trading volume of 1,119,255 shares, compared to its average volume of 649,081. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The firm has a market cap of $606.62 million, a P/E ratio of -10.48 and a beta of 0.97. The company's 50-day simple moving average is $12.91 and its 200 day simple moving average is $13.33.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.